{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T19:00:20Z","timestamp":1777143620845,"version":"3.51.4"},"reference-count":52,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1124\/dmd.120.000318","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T21:45:37Z","timestamp":1624311937000},"page":"844-855","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population"],"prefix":"10.1016","volume":"49","author":[{"given":"Sara N.","family":"Salerno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando O.","family":"Carre\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea N.","family":"Edginton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Cohen-Wolkowiez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.120.000318_bib1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/archdischild-2013-303720","article-title":"Understanding dosing: Children are small adults, neonates are immature children","volume":"98","author":"Anderson","year":"2013","journal-title":"Arch Dis Child"},{"key":"10.1124\/dmd.120.000318_bib2","first-page":"4","article-title":"Abstract 9: The effect of gastric pH on the absorption of ketoconazole by very-low-birth weight infants","volume":"36","author":"Van Den Anker","year":"1994","journal-title":"Pediatr Res"},{"key":"10.1124\/dmd.120.000318_bib3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1473-3099(16)00017-7","article-title":"Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL)","volume":"16","author":"Barrera","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1124\/dmd.120.000318_bib4","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/jps.10539","article-title":"Determination of volume of distribution at steady state with complete consideration of the kinetics of protein and tissue binding in linear pharmacokinetics","volume":"93","author":"Berezhkovskiy","year":"2004","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.120.000318_bib5","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1124\/dmd.109.030676","article-title":"Investigation into UDP-glucuronosyltransferase (UGT) enzyme kinetics of imidazole- and triazole-containing antifungal drugs in human liver microsomes and recombinant UGT enzymes","volume":"38","author":"Bourcier","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000318_bib6","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2146\/ajhp160934","article-title":"Solithromycin: A novel ketolide antibiotic","volume":"74","author":"Buege","year":"2017","journal-title":"Am J Health Syst Pharm"},{"key":"10.1124\/dmd.120.000318_bib7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000457587","article-title":"Development of human liver UDP-glucuronosyltransferases","volume":"13","author":"Burchell","year":"1989","journal-title":"Dev Pharmacol Ther"},{"key":"10.1124\/dmd.120.000318_bib8","unstructured":"DrugBank.DrugBank 5.0 (2018) < https:\/\/go.drugbank.com\/> Accessed Jan 01, 2021."},{"key":"10.1124\/dmd.120.000318_bib9","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/cid\/ciw490","article-title":"SOLITAIRE-IV: A randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia","volume":"63","author":"File","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1124\/dmd.120.000318_bib11","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0090-9556(24)15274-9","article-title":"Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression","volume":"27","author":"Gibbs","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000318_bib12","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1128\/AAC.23.5.787","article-title":"Pharmacology of ketoconazole suspension in infants and children","volume":"23","author":"Ginsburg","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.120.000318_bib13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1128\/AAC.00692-18","article-title":"Population pharmacokinetics and safety of solithromycin following intravenous and oral administration in infants, children, and adolescents","volume":"62","author":"Gonzalez","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.120.000318_bib14","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1128\/AAC.02561-15","article-title":"Solithromycin pharmacokinetics in plasma and dried blood spots and safety in adolescents","volume":"60","author":"Gonzalez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.120.000318_bib15","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1124\/dmd.109.026716","article-title":"The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America","volume":"37","author":"Grimm","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000318_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.xphs.2018.10.033","article-title":"Physiologically based pharmacokinetic modeling in regulatory science: An update from the U.S. Food and Drug Administration\u2019s office of clinical pharmacology","volume":"108","author":"Grimstein","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.120.000318_bib17","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1124\/dmd.105.007658","article-title":"Letter to the editor: Binding of drugs to hepatic microsomes: Comment and assessment of current prediction methodology with recommendation for improvement","volume":"34","author":"Hallifax","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000318_bib18","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/bdd.1810","article-title":"Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption","volume":"34","author":"Harwood","year":"2013","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.120.000318_bib19","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/dmd.31.5.540","article-title":"Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole","volume":"31","author":"Hyland","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000318_bib44","unstructured":"Janssen Pharmaceuticals Nizoral Ketoconazole Tablets. <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/018533s040lbl.pdf> Accessed Jan 01, 2021."},{"key":"10.1124\/dmd.120.000318_bib20","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1038\/psp.2013.55","article-title":"Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children","volume":"2","author":"Jiang","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.120.000318_bib21","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.1365-2125.2001.01370.x","article-title":"Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis","volume":"51","author":"Johnson","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.120.000318_bib22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/bdd.1899","article-title":"Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents","volume":"35","author":"Johnson","year":"2014","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.120.000318_bib23","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1373\/clinchem.2005.050047","article-title":"Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus","volume":"51","author":"Kamdem","year":"2005","journal-title":"Clin Chem"},{"key":"10.1124\/dmd.120.000318_bib24","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology--drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.120.000318_bib25","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1432-1033.1997.00625.x","article-title":"Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth","volume":"247","author":"Lacroix","year":"1997","journal-title":"Eur J Biochem"},{"key":"10.1124\/dmd.120.000318_bib26","doi-asserted-by":"crossref","unstructured":"Lang J, Vincent L, Chenel M, Ogungbenro K, Galetin A (2020) Impact of Hepatic CYP3A4 ontogeny functions on drug\u2013drug interaction risk in pediatric physiologically-based pharmacokinetic\/pharmacodynamic modeling: Critical literature review and ivabradine case study. Clin Pharmacol Ther; Epub Ahead of Print.","DOI":"10.1002\/cpt.2134"},{"key":"10.1124\/dmd.120.000318_bib27","unstructured":"Lexicomp Online (2020) Lexicomp Drug Information. <https:\/\/online.lexi.com\/lco\/action\/login?reauth> Accessed Jan 01, 2021."},{"key":"10.1124\/dmd.120.000318_bib28","doi-asserted-by":"crossref","first-page":"108078","DOI":"10.1016\/j.abb.2019.108078","article-title":"Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism","volume":"673","author":"Li","year":"2019","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.120.000318_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01474-17","article-title":"Metabolism, excretion, and mass balance of solithromycin in Humans","volume":"62","author":"MacLauchlin","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.120.000318_bib30","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1124\/dmd.111.043174","article-title":"Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling","volume":"40","author":"Meyer","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000318_bib31","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.dmpk.2017.11.005","article-title":"Physiological based pharmacokinetic modeling to estimate in vivo Ki of ketoconazole on renal P-gp using human drug-drug interaction study result of fesoterodine and ketoconazole","volume":"33","author":"Oishi","year":"2018","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.120.000318_bib32","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1042\/bj1840705","article-title":"Postnatal development of uridine diphosphate glucuronyltransferase activity towards bilirubin and 2-aminophenol in human liver","volume":"184","author":"Onishi","year":"1979","journal-title":"Biochem J"},{"key":"10.1124\/dmd.120.000318_bib33","first-page":"1","article-title":"Experimental estimation of the role of P-Glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model","volume":"6","author":"Pachot","year":"2003","journal-title":"J Pharm Pharm Sci"},{"key":"10.1124\/dmd.120.000318_bib34","unstructured":"PK-Sim (2017) PK-Sim Ontogeny Database. Version 7.:1\u201347."},{"key":"10.1124\/dmd.120.000318_bib35","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/cpt.409","article-title":"Ontogeny of hepatic drug transporters as quantified by LC-MS\/MS proteomics","volume":"100","author":"Prasad","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.120.000318_bib36","first-page":"465","article-title":"Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes","volume":"57","author":"Rodrigues","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.120.000318_bib37","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40262-014-0140-7","article-title":"A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data","volume":"53","author":"Salem","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.120.000318_bib38","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/jcph.13","article-title":"Do children have the same vulnerability to metabolic drug\u2013drug interactions as adults? A critical analysis of the literature","volume":"53","author":"Salem","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.120.000318_bib39","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/psp4.12252","article-title":"Development of an adult physiologically based pharmacokinetic model of solithromycin in plasma and epithelial lining fluid","volume":"6","author":"Salerno","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.120.000318_bib40","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/cpt.1990","article-title":"Physiologically-based pharmacokinetic modeling characterizes the CYP3A-mediated drug-drug interaction between fluconazole and sildenafil in infants","volume":"109","author":"Salerno","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.120.000318_bib41","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1124\/jpet.103.054841","article-title":"Developmental expression of the major human hepatic CYP3A enzymes","volume":"307","author":"Stevens","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.120.000318_bib42","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/2168479017725558","article-title":"Extrapolation of efficacy in pediatric drug development and evidence-based medicine: Progress and lessons learned","volume":"52","author":"Sun","year":"2018","journal-title":"Ther Innov Regul Sci"},{"key":"10.1124\/dmd.120.000318_bib43","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1248\/bpb.b14-00566","article-title":"Contribution of CYP3A isoforms to dealkylation of PDE5 inhibitors: a comparison between sildenafil N-demethylation and tadalafil demethylenation","volume":"38","author":"Takahiro","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"10.1124\/dmd.120.000318_bib45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1124\/dmd.31.3.275","article-title":"Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation","volume":"31","author":"Tr\u00e9luyer","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000318_bib10","unstructured":"US Food and Drug Administration (FDA) (2020). In vitro metabolism and transporter-mediated drug-drug interaction studies guidance for industry. <https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/vitro-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions> Accessed Jan 01, 2021."},{"key":"10.1124\/dmd.120.000318_bib46","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/jcph.585","article-title":"Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling","volume":"56","author":"Upreti","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.120.000318_bib47","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/j.1875-9114.1984.tb03398.x","article-title":"Ketoconazole mechanism of action, spectrum of activity, drug interactions, adverse reactions and therapeutic use","volume":"4","author":"Van Tyle","year":"1984","journal-title":"Pharmacotherapy"},{"key":"10.1124\/dmd.120.000318_bib48","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/j.1552-4604.1996.tb04251.x","article-title":"Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents","volume":"36","author":"von Moltke","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.120.000318_bib49","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1124\/dmd.30.8.883","article-title":"Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7","volume":"30","author":"Williams","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000318_bib50","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1021\/acs.molpharmaceut.8b01043","article-title":"CYP3A4\/5 activity probed with testosterone and midazolam: Correlation between two substrates at the microsomal and enzyme levels","volume":"16","author":"Xiao","year":"2019","journal-title":"Mol Pharm"},{"issue":"Suppl 1","key":"10.1124\/dmd.120.000318_bib51","first-page":"S160","article-title":"Application of PBPK modeling and simulation for regulatory decision making and its impact on US prescribing information: An Update on the 2018\u20102019 submissions to the US FDA\u2019s office of clinical pharmacology","volume":"60","author":"Zhang","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.120.000318_bib52","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/psp4.12101","article-title":"Predictive performance of physiologically based pharmacokinetic and population pharmacokinetic modeling of renally cleared drugs in children","volume":"5","author":"Zhou","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624079509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624079509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.120.000318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T12:49:54Z","timestamp":1740055794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624079509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0090955624079509"],"URL":"https:\/\/doi.org\/10.1124\/dmd.120.000318","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.120.000318","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}